A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
The purpose of this study is to determine the efficacy and safety of pembrolizumab with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma
Metastatic Urothelial Carcinoma.
1. Male or female age 18 or older
2. Confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial carcinoma of the renal pelvis, ureter [upper urinary track], bladder, or urethra.
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will be in this study for up to about 3 years. Each treatment cycle is 3 weeks. After you finish study treatment your doctor will continue to watch you for side effects and follow your condition every 9 weeks for the first year then every 12 weeks through clinic visits or by telephone until the study ends.
Knight Clinical Trials Information Line
Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co. Inc.)